Multiple reports state that a GP warns people may make potentially dangerous mistakes if they switch from injectable “fat jabs” to a newer, cheaper Wegovy pill. The articles emphasize that the change from injection to tablet is not simply a matter of substituting one product for another, and it may involve differences in dosing, administration, and how patients tolerate treatment. The coverage does not provide detailed clinical results, but it frames the issue as one of safety and correct use during the transition. Overall, the story centers on a caution from a medical professional that patients and prescribers should pay close attention to guidance when changing formulation and treatment route, particularly because cost differences may encourage patients to seek alternatives without appropriate medical supervision. The reports call for careful management of any switch to help reduce the risk of errors in use.